TY - JOUR
T1 - Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations
T2 - A case-control study
AU - Narod, Steven A.
AU - Sun, Ping
AU - Ghadirian, Parviz
AU - Lynch, Henry
AU - Isaacs, Claudine
AU - Garber, Judy
AU - Weber, Barbara
AU - Karlan, Beth
AU - Fishman, David
AU - Rosen, Barry
AU - Tung, Nadine
AU - Neuhausen, Susan L.
N1 - Funding Information:
We thank Patricia de los Rios, Jean-Sebastien Brunet, Marie-Pierre Dubé, and Caitlin Springate for help with the database management and study coordination. The study was supported by the US National Institutes of Health, grants 1RO1 CA 63682, CA 63678, CA 57601, CA61231, and CA74415; the National Cancer Institute of Canada Breast Cancer Research Intitiative; the Department of the Army, grants DAMD17-94-J-4299, DAMD17-J-4260, and DAMD17-J-4340; the American Cancer Society, grant RPG-99-181-01-RCE; the Canadian Genetic Diseases Network; The Canadian Breast Cancer Foundation (Ontario Chapter); the Fonds de La Recherche en Sante du Quebec; the Ontario Cancer Genetics Network; and the Women's Cancer Program of the Dana Farber Cancer Institute. Research was supported by the Utah Cancer Registry which is funded by NCI (NO1-CN-67000) with additional support from the Utah State Department of Health.
PY - 2001/5/12
Y1 - 2001/5/12
N2 - Background In several case-control and prospective studies, tubal ligation has been associated with a decreased risk of invasive epithelial ovarian cancer. We aimed to assess the potential of tubal ligation in reducing the risk of ovarian cancer in women who carry predisposing mutations in the BRCA1 or BRCA2 genes. Methods We did a matched case-control study among women from Canada, the USA, and the UK who had undergone genetic testing and who carried a pathogenic mutation in BRCA1 or BRCA2. Cases were 232 women with a history of invasive ovarian cancer, and controls were 232 women without ovarian cancer, and who had both ovaries intact. Cases and controls were matched for year of birth, country of residence, and mutation (BRCA1 or BRCA2). The odds ratio for developing ovarian cancer was estimated for tubal ligation, adjusting for oral contraceptive use, parity, history of breast cancer, and ethnic group. Findings In an unadjusted analysis among BRCA1 carriers, significantly fewer cases than controls had ever had tubal ligation (30 of 173 [18%] vs 60 of 173 [35%], odds ratio 0·37 [95% CI 0·21-0·63]; p=0·0003). After adjustment for oral contraceptive use, parity, history of breast cancer and ethnic group, the odds ratio was 0·39 (p=0·002). Combination of tubal ligation and past use of an oral contraceptive was associated with an odds ratio of 0·28 (0·15-0·52). No protective effect of tubal ligation was seen among carriers of the BRCA2 mutation. Interpretation Tubal ligation is a feasible option to reduce the risk of ovarian cancer in women with BRCA1 mutations who have completed childbearing.
AB - Background In several case-control and prospective studies, tubal ligation has been associated with a decreased risk of invasive epithelial ovarian cancer. We aimed to assess the potential of tubal ligation in reducing the risk of ovarian cancer in women who carry predisposing mutations in the BRCA1 or BRCA2 genes. Methods We did a matched case-control study among women from Canada, the USA, and the UK who had undergone genetic testing and who carried a pathogenic mutation in BRCA1 or BRCA2. Cases were 232 women with a history of invasive ovarian cancer, and controls were 232 women without ovarian cancer, and who had both ovaries intact. Cases and controls were matched for year of birth, country of residence, and mutation (BRCA1 or BRCA2). The odds ratio for developing ovarian cancer was estimated for tubal ligation, adjusting for oral contraceptive use, parity, history of breast cancer, and ethnic group. Findings In an unadjusted analysis among BRCA1 carriers, significantly fewer cases than controls had ever had tubal ligation (30 of 173 [18%] vs 60 of 173 [35%], odds ratio 0·37 [95% CI 0·21-0·63]; p=0·0003). After adjustment for oral contraceptive use, parity, history of breast cancer and ethnic group, the odds ratio was 0·39 (p=0·002). Combination of tubal ligation and past use of an oral contraceptive was associated with an odds ratio of 0·28 (0·15-0·52). No protective effect of tubal ligation was seen among carriers of the BRCA2 mutation. Interpretation Tubal ligation is a feasible option to reduce the risk of ovarian cancer in women with BRCA1 mutations who have completed childbearing.
UR - http://www.scopus.com/inward/record.url?scp=0035849283&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035849283&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(00)04642-0
DO - 10.1016/S0140-6736(00)04642-0
M3 - Article
C2 - 11377596
AN - SCOPUS:0035849283
VL - 357
SP - 1467
EP - 1470
JO - The Lancet
JF - The Lancet
SN - 0140-6736
IS - 9267
ER -